Radioimmunotherapy is a prostate cancer treatment used to destroy cancer cells that have spread from the prostate to other areas of the body. Radioimmunotherapy is administered intravenously through medications called monoclonal antibodies. These antibodies deliver radiation by seeking out and latching onto proteins found on cancer cells. In order to target the right cells, patients are first administered low-level radioactive antibodies before a full course of radioimmunotherapy is initiated. The number of treatments within a full course of radioimmunotherapy depends on age, weight, overall health, and the type of prostate cancer.
|
